Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

Record History

See every version on ClinicalTrials.gov ↗

1. Notable Sep 28, 2026 Reclassified as terminated (was completed) Sponsor's reason: No dose-limiting toxicity was observed. The sponsor concluded the study after 3 subjects at the higher dose level; the optional 10-subject expansion cohort was not enrolled.v6 Show 4 more changesShow less

   • Phase: Phase 1/2 to Phase 1
   • Primary completion date: Jun 11, 2009 to Sep 29, 2009
   • Study completion date: Jun 11, 2010 to Sep 29, 2009
   • Start date: Jun 2008 to Jun 19, 2008
2. Minor Sep 25, 2026 Trial status: Active, Not Recruiting to Completed

   • Primary completion date changed from estimate of Jun 2013 to Jun 11, 2009
   • Study completion date changed from estimate of Jun 2013 to Jun 11, 2010

   v5
3. Notable Jul 18, 2012 Primary and study completion dates: Feb 2009 to Jun 2013

   • Trial status: Completed to Active, Not Recruiting
   • Enrollment target: estimated 30 to confirmed 7

   v4
4. Oct 12, 2010 Re-verified, no change to tracked fieldsv3
5. Minor Jun 25, 2009 Trial status: Recruiting to Completed

   • Primary and study completion dates changed from estimate of Dec 2008 to Feb 2009
   • Study sites revised (3)

   v2
6. Jul 29, 2008 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.